Moleculin Biotech Inc buy HC Wainwright
Summary
This prediction is currently active. The prediction for Moleculin Biotech Inc disappoints with a performance of -26.13%. This prediction currently runs until 14.12.24. The prediction end date can be changed by HC_Wainwright at any time. HC_Wainwright has 50% into this predictionMoleculin Biotech (Symbol: MBRX) is a clinical-stage pharmaceutical company focused on discovering, developing, and commercializing a broad range of innovative cancer treatments. With a diversified portfolio of drug candidates targeting difficult-to-treat cancers, including leukemia, lung, and pancreatic tumors, MBRX leverages cutting-edge scientific research and expertise to develop drugs that aim to provide improved patient outcomes. The company's innovative approach includes utilizing metabolic inhibitors, immune-globulin-like transcript 3 (ILT3) inhibitors, and STAT3 inhibitors as key weapons in the fight against cancer. As Moleculin Biotech advances its drug candidates through clinical trials, it holds the promise of bringing novel cancer therapies to market, potentially improving the lives of cancer patients globally.
Performance without dividends (%)
| Name | 1w | 1m |
|---|---|---|
| Moleculin Biotech Inc | - | - |
| iShares Core DAX® | -0.051% | 4.829% |
| iShares Nasdaq 100 | 1.659% | 2.417% |
| iShares Nikkei 225® | 0.658% | -2.173% |
| iShares S&P 500 | 0.964% | 2.547% |
Comments by HC_Wainwright for this prediction
In the thread Moleculin Biotech Inc diskutieren